News

A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.

Due to the potential detriment in overall survival, its failure to demonstrate a progression-free survival benefit, and the lack of a known appropriate dose, ODAC has voted that melphalan flufenamide is not favorable in relapsed/refractory multiple myeloma.

Based on the efficacy, toxicity, dose-optimization, and lack of confirmatory data for poziotinib in HER2 exon 20 insertion-positive non–small cell lung cancer, ODAC has voted that the drug has an unfavorable risk/benefit profile.

Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.

Following a report of impressive 2-year follow-up data, the FDA has granted a regular approval to selpercatinib.

Alexander Drilon, MD, discusses what community oncologists should know about testing for  NTRK gene fusions in patients with solid tumors.

Enrollment has begun in the phase 1b trial examining PY159 alone and in combination with pembrolizumab in patients with unresectable and/or metastatic solid tumors that are refractory or relapsed to standard of care.

The FDA has granted approval to Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients.

Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.

Findings of the phase 2 LCMC3 trial of atezolizumab in untreated, resectable, stage IB–IIIB non–small cell lung cancer show anti-PD-L1 monotherapy to be effective in this patient population.

Celsion Corporation announced it had reached enrollment of 110 patients for the OVATION 2 trial of GEN-1 plus neoadjuvant chemotherapy for patients with advanced ovarian cancer.

With extended follow-up, selpercatinib has maintained its efficacy and safety in patients with RET fusion-positive non-small cell lung cancer.

Approval has been granted to aprepitant injectable emulsion by the FDA for the prevention of postoperative nausea and vomiting in adult patients.

William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.

Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.

In an interview with Targeted Oncology, Jonathan Rosenberg, MD, further discussed the background and results of the EV-103 study in patients with locally advanced metastatic urothelial cancer.

Nearly all patients with HR-positive breast cancer are treated with endocrine therapy, yet Black women are 4 times more likely to die of this disease compared with White women.

Andreana Holowatyj, PhD, MSCI, discusses the rationale for her research on the growing increase of early-onset appendiceal cancer in the United States.

A patient with estrogen receptor positive, HER2-negative metastatic breast cancer enrolled in the phase 2 ELAINE 1 trial demonstrated a durable complete response when treated with lasofoxifene.

Robust and durable antitumor activity continues to be shown with pembrolizumab in patients with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

Adam Cohen, MD, discusses the current FDA-approved BCMA-directed therapies in the multiple myeloma space and the clinical data supporting each agent.

In the phase 3 CheckMate-76K study, adjuvant nivolumab administered to patients with stage IIB/C melanoma resulted in prolonged recurrence-free survival compared with placebo.

In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.

Pediatric oncologists are facing unprecedented challenges in the aftermath of the COVID-19 pandemic. In Boston, one cancer institute still has reminiscent encounters with pediatric patients.

In a retrospective analysis of 115 patients with relapsed/refractory multiple myeloma who progressed after therapy on a bispecific antibody, researchers found that the myeloma patients can be salvaged with sequential T-cell redirection therapy.

Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.

In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.

Topline data presented at ESMO 2022 showed DZD9008 met its primary end point of objective response rate and had a benign safety profile in non–small cell lung cancer with EGFR exon 20 insertion mutations.

The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.

David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.